HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026
As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry’s most important global healthcare events. HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held January 12–15, 2026, in San Francisco.
During the conference, Scott Liu, PhD, Founder, Chairman, and CEO, Alvin Luk, PhD, MBA, President & Chief Medical Officer (Group) and Chief Executive Officer (U.S.), together with Yuehua Cong, PhD, Chief Business Officer, are on site meeting with global partners, investors, and industry leaders to discuss collaboration opportunities and HanchorBio’s strategic growth.
HanchorBio is advancing next-generation innate-immunity biologics aimed at transforming cancer immunotherapy, including:
-
HCB101, a next-generation CD47–SIRPα fusion protein designed as an innate-immune backbone for combination therapies with PD-1 inhibitors, anti-VEGF agents, HER2-targeted therapies, EGFR inhibitors, antibody–drug conjugates (ADCs), and radiotherapy
-
HCB301, a tri-specific SIRPα–PD-L1–TGFβ fusion protein designed to reprogram macrophage and T-cell biology
-
FBDB™, HanchorBio’s multi-specific protein engineering platform, enabling programmable immune re-balancing across multiple tumor types
Through innovative science and platform-driven development, HanchorBio remains committed to transforming immunotherapy and advancing health for all.